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Abstract- Glioblastoma Multiforme, the most 
common and aggressive primary brain tumor, 
remains incurable despite of the advent of modern 
surgical and medical treatments. This poor 
prognosis depends by the recurrence after surgery 
and intrinsic or acquired resistance to 
chemotherapy and radiotherapy. Nitric oxide is a 
small molecule that plays a key roles in glioma 
pathophysiology. Many researches showing that NO 
is involved in induction of apoptosis, 
radiosensitization and chemosensitization. 
Therefore, NO role, if clarified, may improve the 
knowledge about this unsolved puzzle called GBM. 
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I. INTRODUCTION 
 
Glioblastoma Multiforme (GBM), a grade IV 
astrocytoma, is the most common and aggressive 
primary brain tumor [1]. Despite the advent of modern 
surgical and medical treatments, GBM remains an 
incurable brain disease with a median patient survival 
time ranging between 12 and 15 months [2-4]. This 
poor prognosis reflects the prevalence of recurrence 
after surgery, infiltration into other sites and intrinsic or 
acquired resistance to chemotherapy and radiotherapy 
[5, 6]. 
Currently, treatment plans involve orally administration 
of temozolomide (TMZ) associated with radiation 
therapy [7]. TMZ, when used with radiation, has been 
able to increase median patient survival from 12.1 to 
14.6 months in comparison to radiotherapy alone [8]. 
The chemoresistance is due to many factors that we 
could divide in extrinsic resistence (like the 
impossibility of drugs to arrive on the tumor for blood-
brain-barrier (BBB)) and intrinsic resistance that is due 
to biological mechanisms of DNA-repair.  
The resistance of tumor cells to the biological effects of 
alkylating agents like TMZ is due to the DNA repair 
protein O6-methylguanine-DNA methyltransferase 
(MGMT) [9, 10]. MGMT is a 22 kDA protein that 
repairs alkylation at the O6 position of guanine on 
DNA strands [10]. Unrepaired alkylation results in the 
induction of apoptosis. Therefore MGMT has an 
important role against chemotherapeutics agents. In 
addition to MGMT, another biomolecule that plays an 
important role in determining chemosensitivity is the 
protein called p53. It plays a critical role in maintaining 
the integrity of the genome and determining cellular 
response, either activating DNA repair mechanisms or   
triggering apoptosis after exposure to damaging stimuli 
such as radiation or chemotherapy [11] (table 1). 
Ionizing radiation (IR) is widely used as a standard 
treatment for GBM [12] and an high dose of IR is often 
fractionated to reduce the side-effects. However, some 
recent studies have demonstrated that IR paradoxically 
determine promotion of specific cells in a malignant 
glioma cell phenotype, determining relapse after 
treatment [13]. In this context, emerging evidence 
suggests that a subpopulation of glioma cells is highly 
tumorigenic and self-renewing, properties reminiscent 
of normal stem cells [14]. These cells constitute a small 
percentage of total GBM cells and their gene 
expression profiles resemble those of normal neural 
stem cells, therefore they have been called glioma 
stem-like cells (GSC). Accordingly GSC are thought to 
be responsible for glioma relapse after treatment and as 
such are regarded as good potential therapeutic targets 
[15, 16]. 
An important modulator of biological therapy response 
could be Nitric Oxide (NO) and we performed a 
literature review to investigate and clarified the role of 
this molecule in GBM therapy.  
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II. METHODOLOGY 
 
A literature search using PubMed MEDLINE database 
has been performed. The search terms “Glioma”, 
“Glioblastoma”, were combined with “Nitric Oxide”, 
“NO synthases”. We investigate the role of NO in 
pathophysiology of glioma and its possible use in 
therapy.  
 
 
III. DISCUSSION 
 
NO is a small, diffusible and short-lived pleiotropic 
molecule, it plays multiple roles as a messenger within 
the human body, including the maintenance of the 
balance between tumor progression and suppression. 
Under physiological conditions, NO is involved in 
multiple cellular processes: 
  
 regulation of vasodilation,  
 cerebral blood flow,  
 vascular permeability may promote tumor cell 
survival at low concentrations [17-19] 
 neurotransmission  
 macrophage-mediated immunity [20] 
Cells produce NO from arginine using enzymes called 
nitric oxide synthases (NOS). There are two types of 
this enzyme: constitutive NOS (cNOS) and inducible 
NOS (iNOS). cNOS include an endothelial cell form 
(eNOS) and a neuronal form (nNOS). nNOS is 
constitutively expressed in brain, eNOS in the 
endothelium of blood vessels, and iNOS in a variety of 
cells such as macrophages or glial cells. eNOS and 
nNOS are calcium-dependent enzymes and generates 
small amounts of NO phasically. Both constitutively 
expressed forms and iNOS work as homodimeric 
enzymes, their activity depend on substrate, L-arginine, 
and cofactors-coenzymes: NADPH (nicotinamide 
adenine dinucleotide phosphate) BH4 
(tetrahydrobiopterin), FMN (flavine mononucleotide), 
FAD (flavin adenine dinucleotide), protoporhyrin IX 
and oxygen. In contrast, iNOS is produced after cells 
stimulus. Compared to nNOS and eNOS, iNOS 
enzyme is not regulated by Ca2+ because is not 
calmodulin dependent even if calmodulin is not 
covalently bound to iNOS. A large amount of NO is 
continuously generated by this calcium-independent 
enzyme. INOS gene expression increases in 
neuroinflammatory conditions. In vitro studies show 
that iNOS expression is promoted by different factors 
such as endotoxin, inflammatory cytochines TNF α, IL 
1β A and IFNγ, hypoxic injury, phorbol ester and 
lipoarabinomannan. More stimulus together contributes 
to iNOS activation in pathological condition. 
Inflammatory cytokines promotes iNOS gene 
transcription: INFγ activates the signal transducer and 
activator of transcription–1, TNFα and IL-1β induce 
the activation of another nuclear transcription factor, 
NF-kb [21]. Many cells types can express iNOS 
activity, including endothelial cells, astrocytes, 
neutrophils, and monocytes/macrophages. In vivo, high 
levels of NO and NOS are found in a great variety of 
lesions, in peripheral areas of stroke following 
ischemia/reperfusion  and during central inflammatory 
reactions. All of these enzymes are encoded by a 
distinct gene [22]. 
 
 
Figure 1 
 
The only known receptor for NO is soluble guanylyl 
cyclase (sGC). The α1β1 heterodimer is the 
predominant isoform of sGC that is obligatory for 
catalytic activity. NO binding at histidine 105 of β1 
subunit leads to sGC activity and cGMP production 
(Fig 1). The NO and 3′,5′-cyclic monophosphate 
(NO/cGMP) pathway plays a central role in many 
physiological processes such as induction of 
vasodilation. On the other hand, the effects of NO can 
be attributed to the cGMP-independent pathway, which 
is mediated mainly by reactive oxygen/nitrogen species 
such as highly reactive peroxynitrite (ONOO) [23]. The 
role of NO and cGMP signaling in tumor biology has 
been extensively studied during the past three decades.  
NO has been shown that affect GBM in great variety of 
ways [24]. It is almost proved the role of NO in 
peritumoural and tumoural cortex, and that the increase 
in NOS activity may play a role in tumour 
vascularization and progression [25]. Many researches 
showing that NO treatment results in the induction of 
apoptosis, radiosensitization and chemosensitization in 
tumor cells, and in increased permeability of the BBB 
[26].  
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Although it is demonstrated that NO exerts anticancer 
effects on tumor growth, it is also demonstrated that it 
can also promotes metastasis or inflammation 
depending on the cellular microenvironment, including 
the quantity of NO, redox status, cell type and cellular 
adaptation [27-12]. Thus, a variety of signaling 
pathways appear to be involved in NO-mediated 
cellular regulation.  
 
 
Figure 2 - Glioblastoma (grade IV): vascular 
proliferation, necrosis, crowded anaplastic cells, 
marked nuclear atypia, brisk mitotic activity 
 
Morand & Col. suggest several reasons for ambiguity 
of NO role in tumor physiopathology: first, although 
NO participates in physiological signaling (e.g., 
vasodilation and neurotransmission), NO is also a 
cytotoxic or apoptotic molecule when produced at high 
concentrations by iNOS. In addition, the cGMP-
dependent (NO/sGC/cGMP pathway) and cGMP-
independent (NO oxidative pathway) components may 
vary among different tissues and cell types (Fig 2). 
Furthermore, solid tumors contain two compartments: 
the parenchyma (tumoral cells) and the stroma 
(supporting tissues including connective tissue, blood 
vessels, and inflammatory cells that are no malignant) 
with different NO biology. Thus, the NO/sGC/cGMP 
signaling molecules in tumors as well as the 
surrounding tissue must be further characterized before 
targeting this signaling pathway for tumor therapy [28]. 
Zhu et Al. found that sGC expression is lower or 
diminished in human glioma tissues and cell lines and 
propose that sGC is a novel tumor susceptibility gene 
in human glioma. Restoring sGC/cGMP signaling 
genetically or pharmacologically significantly inhibited 
glioma growth. Orthotopic xenograftment of glioma 
cells with the α1β1Cys105 sGC stable clone in athymic 
mice increased the survival time by 4-fold over the 
control. This increase in survival time exceeds the 
results recently reported for therapy of glioma with the 
combination of bevacizumab [Avastin; Genentech 
(South San Francisco, CA) VEGF-A antibody] and 
TMZ [29]. Thanks to NO main features (high 
diffusibility to overpass BBB, short half-life, 
modulation of perfusion and apoptosis), this molecule 
could be used in GBM therapy and to get a  response 
modulation of standard GBM therapy. Promising 
experimental strategies of NO-based therapy for 
treatment of GBM are focused on the delivery of high 
NO concentrations into the tumoral cell. Furthermore, 
these strategies are   either focused to increase the drug 
uptake across the BBB, to sensitize tumor cells to 
chemotherapeutic drugs like TMN, to reduce 
radioresistance, and to induce apoptotic cell death 
selectively in tumor cells. Exogenous NO can be 
administered using NO-releasing substances (NO 
donors). Therefore NO donors that release NO for 
prolonged periods are utilized for therapeutic purposes 
[30]. Exposure of tumor cells to NO released from NO 
donors and NO derivates such as peroxynitrite results 
in accumulation of DNA double strand breaks (DSB), 
lipid and protein modifications (such as modification of 
potassium channels by-nitrosylation), and impairment 
of the mitochondrial energy cycle with resultant 
breakdown of cellular energy generation [31]. NO 
released from non-specific NO donors has been shown 
to induce chemosensitivity in glioma cells [32], but 
high doses of NO are lesive to healthy tissue. 
However, these doses are required for therapeutic 
efficacy. In literature, there are papers describing in 
vitro testing on human malignant glioma cells, with 
specific NO donors  targeting only tumoral tissue [34]. 
Chlorotoxin (CTX), a 36 amino acid protein extracted 
from the venom of the Death stalker scorpion (Leiurus 
quinquestraitus), has showed to have an high affinity 
for matrix metalloproteinase-2 (MMP-2) receptors. It 
was observed that these receptors are overexpressed in 
GBM, but not present in the normal brain [34]. CTX 
can be associated with NO gas in order to form an NO-
releasing complex. CTX–NO retains its ability to 
selectively target glioma cells [35]. In in-vitro assay 
using human malignant glioma cells, CTX-NO 
determines a significant reduction in activity levels of 
MGMT, associated with alteration of p53 activity. 
These alterations may led to an increase effect of 
standard chemotherapy whit TMZ,  and play a role in 
decreasing cell invasion [33]. One of the bases of GBM 
therapy, actually, is fractionated IR therapy. IR induces 
DNA DSB, which is the most deleterious of DNA 
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lesions, that can lead to cell death if unrepaired [36]. 
Tumor hypoxia, which occurs mainly as a result 
mismatch between tumor cell growth and blood supply, 
is a challenge for successful radiotherapy [37] (table 1). 
Recent evidence, evaluated on  murine tumor model, 
suggests that IR upregulates NO production and that 
IR-induced NO has the potential to increase 
intratumoral circulation. IR  also increased eNOS 
activity and subsequent tissue perfusion in tumors. This 
led to improvement of tumoral tissue oxygention. Thus,  
IR-induced NO increased tumor radiosensitivity 
against further IR exposure [38]. However, other 
experimental studies in vitro performed on human 
GBM cells, showed that irradiation of glioma cells also 
upregulates NO productionalso from iNOS, which 
promotes GSC selection. In literature, it has been 
described that NO is selectively produced in CD133+ 
glioma cells (GSC), in primary tumor specimens 
through iNOS, and by this up regulation pattern 
promotes GSC expansion [39-14]. Taking into 
consideration other studies, Rae-Kwon Kim,Yongjoon 
Suhet Al. demonstrate that IR-induced expansion of 
GSC might reflect dedifferentiation of glioma cells to 
GSC. These findings could suggest that specific 
targeting of iNOS associated  with IR, might increase 
the efficacy of radiotherapy for GBM treatment [15]. 
 
IV. CONCLUSION 
 
NO is a small, highly diffusible and short-lived 
pleiotropic molecule playing multiple and important 
roles the balance between tumor progression and 
suppression. In literature we found that NO has a very 
complex role in the glioma physiopathology. Some 
evidences show that NO and sGC levels are low in 
glioma cells and restoring sGC/cGMP signaling, we 
can inhibit glioma growth. Moreover, NO released 
from non-specific NO donors has been shown to 
induce chemosensitivity and radiosensitivity. However, 
irradiation of glioma cells also up regulates NO 
production from iNOS and it seems to promotes GSC 
selection. These findings could suggest that specific 
delivery of NO on GBM site could decrease TMZ 
chemoresistance and increase IR efficacy. However,  
increasing of iNOS could select GST inducing relapse 
and multiresistance. Accordingly with these findings, 
we believe that NO should be more investigate because 
it could play a central role in target therapy of 
glioblastoma.
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